Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

被引：0
作者：
F. Caponigro
D. Lorusso
G. Fornari
C. Barone
M. Merlano
M. Airoldi
M. Schena
R. MacArthur
S. Weitman
M. G. Jannuzzo
S. Crippa
F. Fiorentini
A. Petroccione
S. Comis
机构：
[1] National Tumor Institute,
[2] Catholic University,undefined
[3] Valdese Hospital,undefined
[4] S. Croce e Carle Hospital,undefined
[5] S. Giovanni Antica Sede Hospital,undefined
[6] S. Giovanni Battista Hospital,undefined
[7] Columbia University Research Pharmacy,undefined
[8] MCS,undefined
[9] Nerviano Medical Sciences,undefined
[10] Accelera,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Brostallicin; Cisplatin; Phase I; Solid tumors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 394
页数：5
相关论文
共 38 条
[1]  
Geroni C(2002)Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione Cancer Res 62 2332-2336
[2]  
Marchini S(2004)A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors Clin Cancer Res 10 468-475
[3]  
Cozzi P(2003)Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer Clin Cancer Res 9 2957-2964
[4]  
Lockhart AC(2003)Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin Clin Cancer Res 9 5402-5408
[5]  
Howard M(1989)Optimal two-stage design for phase II clinical trials Controll Clin Trials 10 1-10
[6]  
Hande KR(1997)DNA minor groove binding ligands: a new class of anticancer agents Expert Opin Invest Drugs 6 875-884
[7]  
Ten Tije AJ(2001)Development of distamycin-related DNA binding anticancer drugs Expert Opin Invest Drugs 10 1703-1714
[8]  
Verweij J(1991)Selective DNA interaction of the novel distamycin derivative FCE 24517 Cancer Res 51 199-204
[9]  
Sparreboom A(1989)Sequence-specific cleavage of DNA by N-bromoacetyldistamycin. Product and kinetic analyses J Am Chem Soc 111 2700-2712
[10]  
Sabatino MA(1994)Phase I study of the novel distamycin derivative tallimustine (FCE 24517) Ann Oncol 5 901-907
1234